Trial
NCT02779777
Tipifarnib in Subjects With Myelodysplastic Syndromes
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Kura Oncology, Inc.
Collaborators
—
Condition
Myelodysplastic Syndromes
Intervention
Tipifarnib
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-31